trilaciclib + carboplatin + etoposide

This is a **combination regimen** consisting of trilaciclib (a cyclin-dependent kinase 4/6 inhibitor), carboplatin (a platinum-based chemotherapy agent), and etoposide (a topoisomerase II inhibitor), routinely studied and used in the treatment of extensive-stage small cell lung cancer (ES-SCLC)[1][3][5][7][9][10]. Trilaciclib is administered prior to chemotherapy with carboplatin and etoposide to reduce chemotherapy-induced myelosuppression by transiently inhibiting CDK4/6, thereby protecting hematopoietic stem and progenitor cells during cytotoxic chemotherapy[1][7][9]. Carboplatin and etoposide form a standard cytotoxic backbone for SCLC by causing DNA damage and inhibiting cell division[10]. Trials show trilaciclib helps decrease the incidence and duration of severe neutropenia when combined with carboplatin and etoposide[1][5][3]. This regimen does not have a unique brand name as a fixed combination; rather, it is referenced by the constituent drug names in publications and clinical trials.